Alberta Research Chemicals Inc.
$50,400.00 CAD
≈ 8 months of average Canadian pay
- Department
- National Research Council Canada
- Recipient country
- Canada
- Fiscal year
- 2025-2026
- Agreement period
- July 1, 2025 – March 31, 2026
- Reference
- nrc-cnrc:172-2025-2026-Q2-1032220
Published purpose
Firm would like to design and develop novel EGFR (epidermal growth factor receptor) inhibitor cancer therapeutic that improve selectivity to allow irreversible inhibition to overcome resistance mutations. EGFR plays a central role in cell proliferation and survival. Aberrant EGFR signaling is a driver mutation in many tumors, making it an ideal and validated target for cancer therapy. Despite many pharmaceutical companies actively advancing EGFR inhibitors, drug resistance and severe side effects remain unsolved challenges that need to be addressed.
Community tags
Tags are applied by readers, not by this site. One tag per person per record.
Good value
Local impact
Needs context
Questionable
Success story
Wasteful
View official source record
Imported July 30, 2026 from open.canada.ca Grants & Contributions